Skip to main content
All lobbying filings

Todd Strategy Group

Todd Strategy Group filed a Q3 report for Pfizer Inc. on October 19, 2026, reporting $60,000 in lobbying income.

Lobbying for Pfizer Inc. · Biopharmaceutical company.

As filed: TODD STRATEGY GROUP for PFIZER INC.

All filings by Todd Strategy Group · Everything Pfizer Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
District of Columbia

Official filing document

 Lobbyists on this filing 3
  • PAUL EDATTEL
    Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
  • NICHOLAS UEHLECKE
    Previously held: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
  • NICOLAS MAGALLANES
    Previously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification. FDA User Fee Agreements: 2027 PDUFA Cycle. 340B Program Reform. Inflation Reduction Act (IRA). Prior Authorization. Step Therapy Practices. FDA Modernization and Reforms. Drug Pricing. PBM Reform. Vaccine Access and Coverage.

Medicare/Medicaid Issues.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem